



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 16, 2025

David Mehalick  
Chief Executive Officer  
Coeptis Therapeutics Holdings, Inc.  
105 Bradford Road, Suite 420  
Wexford Pennsylvania 15090

**Re: Coeptis Therapeutics Holdings, Inc.  
Registration Statement on Form S-1  
Filed January 10, 2025  
File No. 333-284230**

Dear David Mehalick:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tamika Sheppard at 202-551-8346 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Denis Dufresne